Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib plus bevacizumab in EGFR-mutant advanced non-small cell lung cancer
NL-OMON37461Phase 2Withdrawn
- Sponsor
- European Thoracic Oncology Platform
- Start
- Feb 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by European Thoracic Oncology Platform. Primary endpoint: Progression-free survival. Planned start Feb 2012; status: withdrawn.
02
Drugs
erlotinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON37461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37461.